Alector, Inc. (ALEC)

5,39 +0,05 (+0,94%) Alla chiusura: 04:00PM EDT

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 244

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Arnon Rosenthal Ph.D.	Co-Founder, CEO & Director	1,06M	N/D	1956
Dr. Saraswati Kenkare-Mitra Ph.D.	President and Head of Research & Development	1,29M	N/D	1968
Dr. Marc Grasso M.D.	CFO, Principal Financial Officer & Principal Accounting Officer	728,71k	N/D	1974
Dr. Gary Romano M.D., Ph.D.	Chief Medical Officer	752,17k	N/D	1962
Mr. Peter Heutink Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Katie Hogan	Senior Director of Corporate Communication & Investor Relations	N/D	N/D	N/D
Ms. Danielle Pasqualone J.D., Ph.D.	General Counsel	N/D	N/D	N/D
Ms. Clare Hunt M.B.A.	Chief People Officer	N/D	N/D	N/D
Ms. Kristina Cutter M.P.H.	Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer	N/D	N/D	N/D
Ms. Virginia DeJesus-Rueff M.B.A.	Chief of Staff & Head of Strategy	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Alector, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.